Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study.


Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
12 2021
Historique:
received: 12 04 2021
revised: 28 08 2021
accepted: 01 09 2021
pubmed: 5 10 2021
medline: 27 1 2022
entrez: 4 10 2021
Statut: ppublish

Résumé

The presymptomatic brain changes of granulin (GRN) disease, preceding by years frontotemporal dementia, has not been fully characterized. New approaches focus on the spatial chronnectome can capture both spatial network configurations and their dynamic changes over time. To investigate the spatial dynamics in 141 presymptomatic GRN mutation carriers and 282 noncarriers from the Genetic Frontotemporal dementia research Initiative cohort. We considered time-varying patterns of the default mode network, the language network, and the salience network, each summarized into 4 distinct recurring spatial configurations. Dwell time (DT) (the time each individual spends in each spatial state of each network), fractional occupacy (FO) (the total percentage of time spent by each individual in a state of a specific network) and total transition number (the total number of transitions performed by each individual in a specifict state) were considered. Correlations between DT, FO, and transition number and estimated years from expected symptom onset (EYO) and clinical performances were assessed. Presymptomatic GRN mutation carriers spent significantly more time in those spatial states characterised by greater activation of the insula and the parietal cortices, as compared to noncarriers (p < 0.05, FDR-corrected). A significant correlation between DT and FO of these spatial states and EYO was found, the longer the time spent in the spatial states, the closer the EYO. DT and FO significantly correlated with performances at tests tapping processing speed, with worse scores associated with increased spatial states' DT. Our results demonstrated that presymptomatic GRN disease presents a complex dynamic reorganization of brain connectivity. Change in both the spatial and temporal aspects of brain network connectivity could provide a unique glimpse into brain function and potentially allowing a more sophisticated evaluation of the earliest disease changes and the understanding of possible mechanisms in GRN disease.

Identifiants

pubmed: 34607248
pii: S0197-4580(21)00282-7
doi: 10.1016/j.neurobiolaging.2021.09.001
pii:
doi:

Substances chimiques

Granulins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

155-167

Subventions

Organisme : Medical Research Council
ID : MR/M008525/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M023664/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T046015/1
Pays : United Kingdom
Organisme : CIHR
Pays : Canada

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Enrico Premi (E)

Stroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili Brescia, Brescia, Italy.

Marcello Giunta (M)

Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Armin Iraji (A)

Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, Georgia, USA.

Srinivas Rachakonda (S)

Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, Georgia, USA.

Vince D Calhoun (VD)

Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, Georgia, USA; Departments of Psychology and Computer Science, Georgia State University, Atlanta, USA; Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, USA.

Stefano Gazzina (S)

Neurophysiology Unit, Azienda Socio Sanitaria Territoriale Spedali Civili Brescia, Brescia, Italy.

Alberto Benussi (A)

Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Roberto Gasparotti (R)

Neuroradiology Unit, University of Brescia, Brescia, Italy.

Silvana Archetti (S)

Laboratory Unit, Azienda Socio Sanitaria Territoriale Spedali Civili Brescia, Brescia, Italy.

Martina Bocchetta (M)

Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.

Dave Cash (D)

Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.

Emily Todd (E)

Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.

Georgia Peakman (G)

Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.

Rhian Convery (R)

Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.

John C van Swieten (JC)

Department of Neurology,Erasmus Medical Centre, Rotterdam, Netherlands.

Lize Jiskoot (L)

Department of Neurology,Erasmus Medical Centre, Rotterdam, Netherlands.

Raquel Sanchez-Valle (R)

Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Fermin Moreno (F)

Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain.

Robert Laforce (R)

Clinique Interdisciplinaire de Memoire, Department des Sciences Neurologiques, CHU de Quebec, and Faculte de Medecine, Universite Laval, Quebec, Canada.

Caroline Graff (C)

Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.

Matthis Synofzik (M)

Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tubingen, Tubingen, Germany.

Daniela Galimberti (D)

Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy; University of Milan, Centro Dino Ferrari, Milan, Italy.

James B Rowe (JB)

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Mario Masellis (M)

Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.

Carmela Tartaglia (C)

Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.

Elizabeth Finger (E)

Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario Canada.

Rik Vandenberghe (R)

Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; Neurology Service, University Hospitals Leuven, Leuven, Belgium; Leuven Brain Institute, KU Leuven, Leuven, Belgium.

Alexandre de Mendonça (A)

Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.

Fabrizio Tagliavini (F)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.

Chris R Butler (CR)

Nueld Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.

Isabel Santana (I)

University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Alexander Gerhard (A)

Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.

Isabelle Le Ber (I)

Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Reference Network for Rare Neurological Diseases (ERN-RND).

Florence Pasquier (F)

University of Lille, Inserm, Lille, France.

Simon Ducharme (S)

Neurologische Klinik, Ludwig-Maximilians-Universitat Munchen, Munich, Germany.

Johannes Levin (J)

Neurologische Klinik, Ludwig-Maximilians-Universitat Munchen, Munich, Germany.

Adrian Danek (A)

Department of Neurology, University of Ulm, Ulm, Germany.

Sandro Sorbi (S)

Department of Neurofarba, University of Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.

Markus Otto (M)

Department of Neurology, University of Ulm, Ulm, Germany.

Jonathan D Rohrer (JD)

Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.

Barbara Borroni (B)

Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. Electronic address: bborroni@inwind.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH